Deutsche Bank analyst David Hoang initiates coverage on Kymera Therapeutics (NASDAQ: KYMR) with a Hold rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage